PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.40%
Cash & equivalents declining -13.40% while GNPX's grows 0.00%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-13.40%
Both GNPX and the company show zero Cash + Short-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.47%
Both GNPX and the company show zero Total Current Assets Growth.
8.92%
Higher PP&E (Net) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.91%
Higher Total Non-Current Assets Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Both GNPX and the company show zero Total Assets Growth.
25.71%
Higher Accounts Payable Growth compared to GNPX's zero value, indicating worse performance.
-32.96%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.33%
Higher Other Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
-28.78%
Higher Total Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.78%
Higher Total Liabilities Growth compared to GNPX's zero value, indicating worse performance.
1.95%
Higher Common Stock (Book Value) Growth compared to GNPX's zero value, indicating worse performance.
-3.92%
Both GNPX and the company show zero Retained Earnings Growth.
-19.50%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-8.72%
Both GNPX and the company show zero Total Stockholders' Equity Growth.
-12.20%
Both GNPX and the company show zero Liabilities + Equity Growth.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
13.20%
Higher Net Debt Growth compared to GNPX's zero value, indicating worse performance.